Stock Scorecard



Stock Summary for Cytosorbents Corp (CTSO) - $1.03 as of 4/18/2025 8:45:42 AM EST

Total Score

7 out of 30

Safety Score

11 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CTSO

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CTSO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CTSO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CTSO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CTSO (11 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 2
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CTSO

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller 3/4/2025 12:00:00 PM
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering - CytoSorbents ( NASDAQ:CTSO ) 1/13/2025 12:00:00 PM
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai - CytoSorbents ( NASDAQ:CTSO ) 1/6/2025 12:00:00 PM
Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth - CytoSorbents ( NASDAQ:CTSO ) 1/3/2025 2:49:00 PM
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue 1/3/2025 12:00:00 PM
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue - CytoSorbents ( NASDAQ:CTSO ) 1/3/2025 12:00:00 PM
CytoSorbents Announces Rights Offering 12/9/2024 12:00:00 PM
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification - CytoSorbents ( NASDAQ:CTSO ) 11/4/2024 12:00:00 PM
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review - CytoSorbents ( NASDAQ:CTSO ) 10/22/2024 11:00:00 AM
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results - CytoSorbents ( NASDAQ:CTSO ) 10/17/2024 11:00:00 AM

Financial Details for CTSO

Company Overview

Ticker CTSO
Company Name Cytosorbents Corp
Country USA
Description Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
Sector Name LIFE SCIENCES
Industry Name SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/7/2025

Stock Price History

Last Day Price 1.03
Price 4 Years Ago 4.19
Last Day Price Updated 4/18/2025 8:45:42 AM EST
Last Day Volume 48,720
Average Daily Volume 76,153
52-Week High 1.61
52-Week Low 0.70
Last Price to 52 Week Low 47.14%

Valuation Measures

Trailing PE N/A
Industry PE 68.06
Sector PE 39.26
5-Year Average PE -4.09
Free Cash Flow Ratio 20.60
Industry Free Cash Flow Ratio 149.55
Sector Free Cash Flow Ratio 38.99
Current Ratio Most Recent Quarter 2.20
Total Cash Per Share 0.05
Book Value Per Share Most Recent Quarter 0.20
Price to Book Ratio 5.57
Industry Price to Book Ratio 5.26
Sector Price to Book Ratio 22.22
Price to Sales Ratio Twelve Trailing Months 1.77
Industry Price to Sales Ratio Twelve Trailing Months 4.12
Sector Price to Sales Ratio Twelve Trailing Months 24.77
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 62,500,000
Market Capitalization 64,375,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 1.95%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 27.32%
Reported EPS 12 Trailing Months -0.38
Reported EPS Past Year -0.14
Reported EPS Prior Year -0.38
Net Income Twelve Trailing Months -20,718,957
Net Income Past Year -20,718,957
Net Income Prior Year -28,507,394
Quarterly Revenue Growth YOY 91.60%
5-Year Revenue Growth 1.99%
Operating Margin Twelve Trailing Months -66.80%

Balance Sheet

Total Cash Most Recent Quarter 3,279,926
Total Cash Past Year 3,279,926
Total Cash Prior Year 14,131,137
Net Cash Position Most Recent Quarter -10,716,424
Net Cash Position Past Year -10,716,424
Long Term Debt Past Year 13,996,350
Long Term Debt Prior Year 2,542,857
Total Debt Most Recent Quarter 13,996,350
Equity to Debt Ratio Past Year 0.44
Equity to Debt Ratio Most Recent Quarter 0.44
Total Stockholder Equity Past Year 11,106,936
Total Stockholder Equity Prior Year 23,275,163
Total Stockholder Equity Most Recent Quarter 11,106,936

Free Cash Flow

Free Cash Flow Twelve Trailing Months -15,097,238
Free Cash Flow Per Share Twelve Trailing Months -0.24
Free Cash Flow Past Year -14,712,152
Free Cash Flow Prior Year -22,591,372

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.02
MACD Signal -0.02
20-Day Bollinger Lower Band 0.84
20-Day Bollinger Middle Band 1.02
20-Day Bollinger Upper Band 1.19
Beta 1.17
RSI 50.31
50-Day SMA 1.02
150-Day SMA 1.72
200-Day SMA 2.61

System

Modified 4/16/2025 10:15:33 PM EST